Molecular Oncology (Jul 2023)

Codon adaptation by synonymous mutations impacts the functional properties of the estrogen receptor‐alpha protein in breast cancer cells

  • Léa Clusan,
  • Frederic Percevault,
  • Emmanuelle Jullion,
  • Pascale Le Goff,
  • Christophe Tiffoche,
  • Tamara Fernandez‐Calero,
  • Raphaël Métivier,
  • Monica Marin,
  • Farzad Pakdel,
  • Denis Michel,
  • Gilles Flouriot

DOI
https://doi.org/10.1002/1878-0261.13399
Journal volume & issue
Vol. 17, no. 7
pp. 1302 – 1323

Abstract

Read online

Oestrogen receptor‐alpha (ERα) positivity is intimately associated with the development of hormone‐dependent breast cancers. A major challenge in the treatment of these cancers is to understand and overcome the mechanisms of endocrine resistance. Recently, two distinct translation programmes using specific transfer RNA (tRNA) repertoires and codon usage frequencies were evidenced during cell proliferation and differentiation. Considering the phenotype switch of cancer cells to more proliferating and less‐differentiated states, we can speculate that the changes in the tRNA pool and codon usage that likely occur make the ERα coding sequence no longer adapted, impacting translational rate, co‐translational folding and the resulting functional properties of the protein. To verify this hypothesis, we generated an ERα synonymous coding sequence whose codon usage was optimized to the frequencies observed in genes expressed specifically in proliferating cells and then investigated the functional properties of the encoded receptor. We demonstrate that such a codon adaptation restores ERα activities to levels observed in differentiated cells, including: (a) an enhanced contribution exerted by transactivation function 1 (AF1) in ERα transcriptional activity; (b) enhanced interactions with nuclear receptor corepressor 1 and 2 [NCoR1 and NCoR2 (also known as SMRT) respectively], promoting repressive capability; and (c) reduced interactions with SRC proto‐oncogene, non‐receptor tyrosine kinase (Src) and phosphoinositide 3‐kinase (PI3K) p85 kinases, inhibiting MAPK and AKT signalling pathway.

Keywords